Page 179 - Haematologica3

In vivo IL-12/IL-23p40 neutralization
1995;15(6):825-828.
17. Filipovich AH, Weisdorf D, Pavletic S, et al.
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
18. Pidala J, Kim J, Jim H, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrex- ate after allogeneic hematopoietic cell transplantation. Haematologica. 2012; 97(12):1882-1889.
19. Gray R. A class of K-sample tests for com- paring the cumulative incidence of a com- peting risk. Annals Of Statistics 1988; 16(3):1141-1154.
20. Hartwell MJ, Ozbek U, Holler E, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI
Insight. 2017;2(3):e89798.
21. Vander Lugt MT, Braun TM, Hanash S, et
al. ST2 as a marker for risk of therapy-resis- tant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.
22. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a bio- marker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-6708.
23. Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem- cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451-1459.
24. Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015; 21(7):719-729.
25. Trinchieri G. Interleukin-12 and the regula-
tion of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-146.
26. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunothera- py. Cytokine Growth Factor Rev. 2002; 13(2):155-168.
27. Ngiow SF, Teng MW, Smyth MJ. A balance of interleukin-12 and -23 in cancer. Trends Immunol. 2013;34(11):548-555.
28. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844-854.
29. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell trans- plantation. Blood. 2014;123(23):3664-3671.
haematologica | 2018; 103(3)
539